German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Graduate School of Systemic Neuroscience, Ludwig-Maximilians-University, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Alessio Vittorio Colombo
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Gaye Tanrioever
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany; Department of Cellular Neurology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
Jasmin König
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Faculty of Chemistry, Technical University of Munich, Garching, Germany
Stefan Roth
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, Germany
Arthur Liesz
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
Anna Berghofer
Neuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technical University, Munich, Germany
Anke Piechotta
Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany
Matthias Prestel
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, Germany
Takashi Saito
Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Institute, Wako, Japan; Department of Neurocognitive Science, Nagoya City University Graduate School of Medical Science, Nagoya, Japan
Takaomi C Saido
Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Institute, Wako, Japan
Jochen Herms
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität München, Munich, Germany
Michael Willem
Biomedical Center (BMC), Ludwig-Maximilians Universität München, Munich, Germany
Christian Haass
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Biomedical Center (BMC), Ludwig-Maximilians Universität München, Munich, Germany
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Neuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technical University, Munich, Germany
Microglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is known about proteome-wide changes in microglia during the course of AD and their functional consequences. Here, we performed an in-depth and time-resolved proteomic characterization of microglia in two mouse models of amyloid β (Aβ) pathology, the overexpression APPPS1 and the knock-in APP-NL-G-F (APP-KI) model. We identified a large panel of Microglial Aβ Response Proteins (MARPs) that reflect heterogeneity of microglial alterations during early, middle and advanced stages of Aβ deposition and occur earlier in the APPPS1 mice. Strikingly, the kinetic differences in proteomic profiles correlated with the presence of fibrillar Aβ, rather than dystrophic neurites, suggesting that fibrillar Aβ may trigger the AD-associated microglial phenotype and the observed functional decline. The identified microglial proteomic fingerprints of AD provide a valuable resource for functional studies of novel molecular targets and potential biomarkers for monitoring AD progression or therapeutic efficacy.